TERBUNY, Russia, Sept. 10, 2013 /PRNewswire/ -- Rafarma
Pharmaceuticals, Inc., OTC symbol "RAFA," announced it has entered
into a new multi-year distribution contract with Amber Pharma
Distribution Group, a boutique international business development
firm. The principals of Amber Pharma have more than 75 years of
combined international business development experience in a wide
range of industry sectors including pharmaceuticals, finance,
software, telecommunications and trade. It is intended that
this new alliance with Rafarma will lead to over $100 million USD in new sales within the next 24
to 36 months.
CEO Dave Anderson stated: "We are
delighted to form this strategic alliance with Amber Pharma. This
is just the beginning of Rafarma's aggressive expansion into
producing high-quality pharmaceutical products with partners all
over the globe. If any distributor, supplier or retail provider is
looking for state-of-the-art pharma production at competitive
pricing, the Terbuny plant is the place, and its production
capacity is still expanding."
About Rafarma Pharmaceuticals, Inc.
Operating from a new 270,000 square-foot state-of-the-art
manufacturing and distribution facility in Russia, Rafarma Pharmaceuticals produces
generic antibiotics and specialty pharmaceuticals in addition to
its own line of proprietary products that are approved by the
Ministry of Health of Russian
Federation. For the last three years, the Russian Government
has been highly focused on bolstering the development of the
nation's domestic pharmaceutical industry. Rafarma Pharmaceuticals'
mission is to work with the auspices of aggressive federal
initiatives to fast-track the modernization of Russia's pharmaceutical industry.
For more information on Rafarma Pharmaceuticals, visit:
http://rafarma.com
Safe Harbor Statement
Matters discussed in this press release contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. When used in this press release, the words
"anticipate," "believe," "estimate," "may," "intend," "expect" and
similar expressions identify such forward-looking statements.
Actual results, performance or achievements could differ materially
from those contemplated, expressed or implied by the
forward-looking statements contained herein. These forward-looking
statements are based largely on the expectations of the Company and
are subject to a number of risks and uncertainties. These include,
but are not limited to: the impact of economic, competitive and
other factors affecting the Company and its operations, markets,
product, and distributor performance.
RELATED LINKS
Website: www.Rafarma.com
Facebook: www.facebook.com/Rafarmainfo
Twitter: www.twitter.com/Rafarmainfo
SOURCE Rafarma Pharmaceuticals, Inc.